Figure 8.

Efficacy of MeV-CD-F^miRTS148a chemovirotherapy in vivo

Subcutaneous T3M4 tumors were implanted into the right flank of NOD/SCID/gamma mice. On day 9 post-implantation, mice were treated with daily intratumoral injections of MeV-CD-F^miRTS148a (6.9 × 10⁶ CIU) for 5 days. Starting 48 h after the first virus injection, intraperitoneal 5-FC (200 mg/kg) was applied twice daily for 5 days. Control-treated mice received either MeV-CD-F^miRTS148a, 5-FC, or mock treatment. A total number of 36 animals were treated in the study (n = 9 per group). (A) Tumor growth dynamics of individual mice. Arrows indicate intratumoral injections, and gray areas mark the duration of intraperitoneal treatments. (B) Tumor growth trajectories aggregated by treatment group. Regression lines (dashed) based on the data in (A) with 95% confidence bands (colored) are shown. (C) Tumor volume of individual mice (gray) on day 16 after tumor implantation (the last day all animals were alive). Horizontal bars indicate mean values. (D) Kaplan-Meier survival analysis; p-value was obtained by log-rank test comparing MeV-CD-F^miRTS148a + 5-FC and MeV-CD-F^miRTS148a alone.